How does complementary private prescription drug insurance coverage affect seniors’ use of publicly funded medications?
Like in many other high-income jurisdictions, the public drug program in Ontario, Canada provides comprehensive coverage of prescription drugs to the 65 years and older population with some cost sharing. The objective of this study was to examine the marginal impact of holding private drug coverage on the use of publicly funded medicines among the senior population in Ontario.
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- P Grootendorst, 1999. "Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment," Centre for Health Economics and Policy Analysis Working Paper Series 1999-10, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
- Baoping Shang & Dana Goldman, 2010. "Prescription Drug Coverage and Medicare Spending among U.S. Elderly*," The Geneva Papers on Risk and Insurance - Issues and Practice, Palgrave Macmillan, vol. 35(4), pages 539-567, October.
- Hanming Fang & Michael P. Keane & Dan Silverman, 2006.
"Sources of Advantageous Selection: Evidence from the Medigap Insurance Market,"
NBER Working Papers
12289, National Bureau of Economic Research, Inc.
- Hanming Fang & Michael P. Keane & Dan Silverman, 2008. "Sources of Advantageous Selection: Evidence from the Medigap Insurance Market," Journal of Political Economy, University of Chicago Press, vol. 116(2), pages 303-350, 04.
- Fang, Hanming & Keane, Michael & Silverman, Dan, 2006. "Sources of Advantageous Selection: Evidence from the Medigap Insurance Market," Working Papers 17, Yale University, Department of Economics.
- Devlin, Rose Anne & Sarma, Sisira & Zhang, Qi, 2011. "The role of supplemental coverage in a universal health insurance system: Some Canadian evidence," Health Policy, Elsevier, vol. 100(1), pages 81-90, April.
- Sara Allin & Jeremiah Hurley, 2009.
"Inequity in publicly funded physician care: what is the role of private prescription drug insurance?,"
John Wiley & Sons, Ltd., vol. 18(10), pages 1218-1232.
- Sara Allin & Jeremiah Hurley, 2008. "Inequity in Publicly Funded Physician Care: What Is The Role Of Private Prescription Drug Insurance?," Centre for Health Economics and Policy Analysis Working Paper Series 2008-02, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada.
- Sara Allin & Audrey Laporte, 2011. "Socioeconomic Status and the Use of Medicines in the Ontario Public Drug Program," Canadian Public Policy, University of Toronto Press, vol. 37(4), pages 563-576, December.
- Finkelstein, Amy, 2002. "The effect of tax subsidies to employer-provided supplementary health insurance: evidence from Canada," Journal of Public Economics, Elsevier, vol. 84(3), pages 305-339, June.
- Mark Stabile, 2001. "Private insurance subsidies and public health care markets: evidence from Canada," Canadian Journal of Economics, Canadian Economics Association, vol. 34(4), pages 921-942, November.
When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:110:y:2013:i:2:p:147-155. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Shamier, Wendy)or ()
If references are entirely missing, you can add them using this form.